NJ-LABVANTAGE-SOLUTIONS
25.3.2021 12:32:05 CET | Business Wire | Press release
LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services, including purpose-built LIMS solutions that allow labs to go live faster and at a lower total cost, today announced the appointment of Mikael Hagstroem as Chief Executive Officer. Mr. Hagstroem brings LabVantage almost 30 years of experience as a pioneer and expert in digital transformation, helping global enterprises harness data and analytics to reimagine their business models, achieve better performance, and create a long-term sustainable advantage.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210325005048/en/
In his 25 years at the SAS Institute, Mr. Hagstroem helped build the analytics software powerhouse into a multibillion-dollar enterprise that is one of the world’s largest privately held software businesses. His client focus and success in consistently growing sales and profits resulted in assignments of increasing responsibility. He ultimately held the positions of Executive Vice President of SAS and President of SAS International, with P&L responsibility for more than half of total corporate revenues.
Mr. Hagstroem then became a Partner at McKinsey & Company and Chief Operating Officer of McKinsey Analytics, which helps companies create and scale new delivery models for analytics and artificial intelligence (AI). Most recently he was CEO and President at MetricStream, the world’s largest independent provider of governance, risk, and compliance products and solutions, where he led its transformation to a software as a service (SaaS) model, launched its Integrated Risk Management Platform, and championed integration of AI features into the platform.
A respected strategist and opinion leader in the fields of analytics, digital transformation and AI, Mr. Hagstroem is currently on the Board of Advisors of the AI Forum and has served as Chair of the World Economic Forum’s Global Agenda Council on Data-Driven Development, as a member of the Executive Committee of the U.S. Council for International Business, and as an Executive Board member of the Atlantic Council. He is also an Independent Director of Planet Smart City, which integrates architectural, digital, and environmental solutions to deliver high-quality low-cost housing.
“Mikael embodies the sense of purpose and passion required to tackle big goals and the expertise to achieve them,” said Dr. Purnendu Chatterjee, Chairman of LabVantage Solutions. “He is an accomplished business leader who has built innovative data-based enterprises across a range of industries. He is a visionary strategist who understands the transformational potential of advanced technologies and translates them into actionable business initiatives. An inspired leader, Mikael is committed to accelerating the use of new tools such as analytics and AI to address urgent global problems. We are thrilled to welcome him to LabVantage and excited at the prospect of what we can accomplish together.”
“LabVantage brings the Fourth Industrial Revolution−characterized as a range of new technologies that are fusing the physical, digital and biological worlds and impacting all disciplines, economies and industries−to the lab, and I am honored to take the helm,” said Mr. Hagstroem. “LabVantage is on the forefront of innovation, incorporating advanced technologies in easy-to-use solutions that are making the digital transformation of the laboratory a reality. The company has tremendous opportunities working at the intersection of the biological and digital revolutions, allowing us to help customers solve ever more complex problems and achieve disruptive growth. I look forward to working with the talented LabVantage team at this unique time when our future has never been brighter.”
About LabVantage Solutions
A recognized leader in enterprise laboratory software solutions, LabVantage Solutions dedicates itself to improving customer outcomes by transforming data into knowledge. The LabVantage informatics platform is highly configurable, integrated across a common architecture, and 100% browser-based to support hundreds of concurrent users. Deployed on-premise, via the cloud, or SaaS, it seamlessly interfaces with instruments and other enterprise systems – enabling true digital transformation. The platform consists of the most modern laboratory information management system (LIMS) available, integrated electronic laboratory notebook (ELN), laboratory execution system (LES), scientific data management system (SDMS), and advanced analytics; and, for healthcare settings, a laboratory information system (LIS). We support more than 1500 global customer sites in the life sciences, pharmaceutical, medical device, biobank, food & beverage, consumer packaged goods, oil & gas, genetics/diagnostics, and healthcare industries. Headquartered in Somerset, NJ, with global offices, LabVantage has offered its comprehensive portfolio of products and services to enable customers to innovate faster in the R&D cycle, improve manufactured product quality, achieve accurate record-keeping, and comply with regulatory requirements for four decades. For more information, visit labvantage.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210325005048/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Splio Enters a New Phase of Its Regional Development in Southern Europe19.5.2026 09:00:00 CEST | Press release
As consumers integrate AI into their everyday web usage, Splio is strengthening its presence in Barcelona to help companies across the region make CRM a central lever in the age of agentic commerce Splio is strengthening its presence in Barcelona, which is set to play the role of a second headquarters, to drive its development across Southern Europe.Splio is reinforcing governance, teams and resources deployed in the region.With its AI-first CRM, Splio aims to help companies from retail to travel strengthen the business contribution of CRM. A few months after launching its AI-first CRM, Splio is entering a new phase of its development in Southern Europe. Already established for more than 12 years in Spain, Portugal and Italy, the company has chosen to invest further in the region, convinced that it combines economic potential with rapidly evolving digital usage. Antoine Parizot, Splio’s co-CEO, is relocating to Barcelona, where the company’s historic office is based. At the same time,
KfW, Germany’s largest national promotional bank, future-proofs regulatory reporting, by migrating to Regnology Reporting Hub (RRH)19.5.2026 08:33:00 CEST | Press release
Longstanding client transitions to the next-generation RRH solution, delivered on Regnology’s Rcloud architecture Regnology, a leading provider at the intersection of regulatory, risk, and supervisory technology, today announced that KfW Bankengruppe (KfW) is advancing its long-term partnership with the company by electing to migrate to the next-generation Regulatory Reporting Hub (RRH). The solution will be delivered as a cloud-native service on Rcloud, Regnology’s high-performance cloud architecture layer. This strategic move to the modern RRH platform future-proofs the mission-critical reporting functions for one of the world's leading promotional banks. Headquartered in Frankfurt am Main, KfW is a public‑law institution dedicated to supporting sustainable economic, social and ecological development in Germany, across Europe and globally. Regnology’s foresight led to the 2023 launch of Rcloud, its state-of-the-art architecture layer built on Google Cloud, enabling next‑generation so
ATB Therapeutics Appoints Mark Throsby as CEO to Lead Next Phase of Growth19.5.2026 08:00:00 CEST | Press release
ATB Therapeutics (“ATB” or the “Company”), a biopharmaceutical company advancing next-generation antibody-based therapies for oncology and immunology, today announced the appointment of Mark Throsby, PhD, as Chief Executive Officer. The leadership transition marks an important milestone as the Company continues its evolution from a startup into a development-stage biopharmaceutical company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513198633/en/ ATB Therapeutics Appoints Mark Throsby as CEO to Lead Next Phase of Growth Mark Throsby has served as Executive Chairman and Chief Scientific Officer since 2024, during which time he supported the Company’s growth, including the successful closing of its Series A financing, the expansion of the scientific team, and the advancement of its therapeutic programs. In his new role, he will lead ATB’s strategy and senior leadership team as the Company prepares to enter clinical deve
TREASoURcE Shows How Circular Economy Solutions Can Move Beyond Pilots Across Sectors and Regions19.5.2026 07:00:00 CEST | Press release
Across Europe, many circular economy solutions struggle to move beyond isolated pilots and into real-world deployment at scale. New approaches are needed that combine technical feasibility, market relevance and citizen engagement, while remaining adaptable to local contexts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260518914041/en/ TREASoURcE addressed circular economy challenges across energy, plastics and biobased side streams, combining technical solutions with stakeholder and citizen engagement. The EU-funded TREASoURcE project provides evidence that systemic, citizen-engaged circular economy solutions can be developed, tested and prepared for replication across regions. Using a common regional approach, the project combined real-life demonstrations, cross-value chain collaboration and early consideration of transferability to translate circular economy concepts into practical solutions in the fields of energy, mat
Azafaros Strengthens Leadership Team With Appointment of Amy Sullivan as Chief Financial Officer19.5.2026 07:00:00 CEST | Press release
Experienced biotech finance leader with over 30 years’ experience in capital markets and strategyProven track record in fundraising, M&A and company transformationCompany is currently running two pivotal Phase 3 studies with nizubaglustat in GM1/ GM2 gangliosidoses and Niemann-Pick type C disease Azafaros, a private company building a portfolio to become a leader in Lysosomal Storage Disorders and focused on addressing neurological symptoms, today announced that Amy Sullivan has joined the company as Chief Financial Officer. Ms. Sullivan brings more than 30 years’ experience in the life sciences sector, with expertise in capital raising, corporate strategy and communications. She joins Azafaros from IO Biotech, where she served as Chief Financial Officer. “Amy is a highly accomplished financial leader with a strong track record of supporting growth-stage biotech companies,” said Stefano Portolano, Chief Executive Officer at Azafaros. “Her expertise in financing, strategic positioning a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
